Prophylactic HPV vaccines: the Finnish perspective

References

• zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account. Virology384, 260–265 (2009).
   PubMed Web of Science ®Google Scholar
• Syrjänen S, Syrjänen K. The history of papillomavirus research. Cent. Eur. J. Pub. Health16, S7–S13 (2008).
   Google Scholar
• Pyrhönen S, Penttinen K. Wart virus antibodies and the prognosis of wart disease. Lancetii, 1330–1332 (1972).
   Google Scholar
• Pyrhönen S, Johansson E. Regression of warts. An immunological study. Lanceti, 592–596 (1975).
   Google Scholar
• Purola E, Savia E. Cytology of gynecologic condyloma acuminatum. Acta Cytol.21, 26–31 (1977).
   PubMed Web of Science ®Google Scholar
• Syrjänen KJ. Histological changes identical to those of condylomatous lesions found in esophageal squamous cell carcinomas. Arch. Geschwulstforsch52, 283–292 (1982).
   PubMedGoogle Scholar
• Syrjänen KJ, Pyrhönen S, Syrjänen SM. Evidence suggesting human papillomavirus (HPV) etiology for the squamous cell papilloma of the paranasal sinus.Arch. Geschwulstforsch.53, 77–82 (1983).
   PubMedGoogle Scholar
• Syrjänen KJ, Pyrhönen S, Syrjänen SM, Lamberg MA. Immunohistochemical demonstration of human papilloma virus (HPV) antigens in oral squamous cell lesions. Br. J. Oral Surg.21, 147–153 (1983).
   PubMedGoogle Scholar
• Syrjänen KJ, Syrjänen SM, Pyrhönen S. Human papilloma virus (HPV) antigens in lesions of laryngeal squamous cell carcinomas. ORL44, 323–334 (1982).
   Google Scholar
• Syrjänen KJ. Condylomatous changes in neoplastic bronchial epithelium. Report of a case. Respiration38, 299–304 (1979).
   PubMedGoogle Scholar
• Syrjänen K, de Villiers E-M, Väyrynen M, Mäntyjärvi R, Parkkinen S, Castren O. Cervical papillomavirus infection progressing to invasive cancer in less than three years. Lanceti, 510–511 (1985).
   Google Scholar
• Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer95, 1459–1466 (2006).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367, 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med.347, 1645–1651 (2002).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet364, 1757–1765 (2004).
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol.6, 271–278 (2005).
   PubMed Web of Science ®Google Scholar
• The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med.356, 1915–1926 (2007).
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med.356, 1928–1943 (2007).
   PubMed Web of Science ®Google Scholar
• Joura EA, Leodolter S, Hernandez-Avila M et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet369, 1693–1702 (2007).
   PubMed Web of Science ®Google Scholar
• Olsson SE, Villa LL, Costa RL et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine25, 4931–4939 (2007).
   PubMed Web of Science ®Google Scholar
• Harper DM. Impact of vaccination with Cervarix™ on subsequent HPV-16/18 infection and cervical disease in women 15–25 years of age. Gynecol. Oncol.110, S11–S17 (2008).
   Google Scholar
• Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet369, 2161–2170 (2007).
   PubMed Web of Science ®Google Scholar
• Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine26(Suppl. 10), K53–K61 (2008).
   PubMed Web of Science ®Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J. Infect. Dis.199, 926–935 (2009).
   PubMed Web of Science ®Google Scholar
• Majewski S, Bosch FX, Dillner J et al. The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. J. Eur. Acad. Dermatol. Venereol.23(10), 1147–1155 (2009).
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet374, 301–314 (2009).
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J. Infect. Dis.199, 936–944 (2009).
   PubMed Web of Science ®Google Scholar
• Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine26, 6244–6257 (2008).
   PubMedGoogle Scholar
• Bosch FX. A scientific response to prevent cervical cancer in the world. Vaccine26(Suppl. 10), v–vi (2008).
   Google Scholar
• De Carvalho NS. Cervical cancer vaccination: the real meaning of cross-protection and its impact on the prevention. Vaccine26, 6293–6294 (2008).
   PubMedGoogle Scholar
• Franco EL, Tsu V, Herrero R et al. Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean. Vaccine26(Suppl. 11), L88–L95 (2008).
   Google Scholar
• Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine26(Suppl. 1), A16–A23 (2008).
   PubMed Web of Science ®Google Scholar
• Garland SM, Cuzick J, Domingo EJ et al. Recommendations for cervical cancer prevention in Asia Pacific. Vaccine26(Suppl. 12), M89–M98 (2008).
   Google Scholar
• Goldie SJ, O’Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine26, 4080–4093 (2008).
   PubMed Web of Science ®Google Scholar
• Harper DM. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health. Public Health Genomics12, 319–330 (2009).
   PubMed Web of Science ®Google Scholar
• Monsonego J. The new challenges in the prevention of cervical cancer. Vaccine26(Suppl. 1), A4–A6 (2008).
   Google Scholar
• Saslow D, Castle PE, Cox JT et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J. Clin.57, 7–28 (2007).
   PubMed Web of Science ®Google Scholar
• Michels KB, zur Hausen H. HPV vaccine for all. Lancet374(9686), 268–270 (2009).
   PubMed Web of Science ®Google Scholar
• Hakama M. Screening for cervical cancer: Experience from the Nordic countries. In: New Developments in Cervical Cancer Screening and Prevention. Franco E, Monsonego J (Eds). Blackwell Science, Oxford, UK, 190–199 (1997).
   Google Scholar
• Hildesheim A, Markowitz L, Avila MH, Franceschi S. Chapter 27: research needs following initial licensure of virus-like particle HPV vaccines. Vaccine24(Suppl. 3), S227–S232 (2006).
   Google Scholar
• Lehtinen M, French K, Dillner J, Paavonen J, Garnett G. Sound implementation of HPV vaccination. Therapy5(3), 289–294 (2008).
   Google Scholar
• Donner A, Klar N. Pitfalls of and controversies in cluster randomization trials. Am. J. Pub. Med.94, 416–422 (2004).
   PubMed Web of Science ®Google Scholar
• Kerry SM, Bland JM. The intercluster correlation coefficient in cluster randomization. BMJ316, 1455 (1998).
   PubMed Web of Science ®Google Scholar
• Syrjänen KJ. Quality assurance in the cytopathology laboratories of the Finnish Cancer Society. In: Compendium on Quality Assurance, Proficiency Testing and Workload Limitations in Clinical Cytology. Wied GL, Keebler CM, Rosenthal DL, Schenck U, Somrak TM, Vooijs GP (Eds). Tutorials of Cytology, IL, USA, 134–142 (1995).
   Google Scholar
• Syrjänen K. Early detection of CIN, HPV and prevention of cervical cancer. In: Papillomavirus Infections in Human Pathology. Syrjänen K, Syrjänen S (Eds). John Wiley & Sons, NY, USA, 252–280 (2000).
   Google Scholar
• Anttila A, Pukkala E, Söderman B, Kallio M, Nieminen P, Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963–1995: recent increase in cervical cancer incidence. Int. J. Cancer83, 59–65 (1999).
   PubMed Web of Science ®Google Scholar
• Syrjänen K, Shabalova I, Naud P et al.; New Independent States of the Former Soviet Union and the Latin American Screening Study Research Groups. Persistent high-risk human papillomavirus infections and other endpoint markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study cohorts. Int. J. Gynecol. Cancer19, 934–942 (2009).
   PubMedGoogle Scholar
• Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM. Cost–effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine26, 128–139 (2007).
   PubMed Web of Science ®Google Scholar
• Zechmeister I, Blasio BF, Garnett G, Neilson AR, Siebert U. Cost–effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine27, 5133–5141 (2009).
   PubMed Web of Science ®Google Scholar
• Syrjänen KJ. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland. Scand. J. Infect. Dis.41(Suppl. 107), 3–32 (2009).
   Web of Science ®Google Scholar
• Syrjänen KJ. Annual disease burden due to human papillomavirus (HPV) 16 and 18 infections in Finland. Scand. J. Infect. Dis.41(Suppl. 108), 2–32 (2009).
   Web of Science ®Google Scholar
• Syrjänen K, Syrjänen S. Papillomavirus Infections in Human Pathology. John Wiley & Sons, Chichester, UK (2000).
   Google Scholar
• Bosch FX. Broad-spectrum human papillomavirus vaccines: new horizons but one step at a time. J. Natl Cancer Inst.101, 771–773 (2009).
   PubMedGoogle Scholar
• Franceschi S, Cuzick J, Herrero R, Dillner J, Wheeler CM. EUROGIN 2008 roadmap on cervical cancer prevention. Int. J. Cancer125, 2246–2255 (2009).
   PubMedGoogle Scholar
• Franco EL, Coutlee F, Ferenczy A. Integrating human papillomavirus vaccination in cervical cancer control programmes. Public Health Genomics12, 352–361 (2009).
   PubMedGoogle Scholar
• Harper D. Currently approved prophylactic HPV vaccines. Expert Rev. Vaccines8(12), 1663–1679 (2009).
   PubMed Web of Science ®Google Scholar